Reviewed by scientists at the Department of Health and Human Services, the research grant has been awarded to X-BODY for its human monoclonal antibody therapeutic project targeting metastatic tumor stem cells.
The grant provides X-BODY with the maximum allowable 50% reimbursement of its qualified investment of ~$500,000 in this project.
The company claims that its therapeutic candidates target a kinase signaling pathway that is believed to mediate metastasis (invasion and spreading) of cancer tumor initiating stem cells.
X-BODY said that its pre-clinical candidates were discovered using a proprietary platform, based on a new screening technology allowing for rapid generation of human antibody therapeutics of high affinity and selectivity, via deep sequence interrogation of fully human DNA libraries.